NDC product
Olanzapine and Fluoxetine
NDC 0093-5505 · Teva Pharmaceuticals USA, Inc.
Key facts
| Product NDC | 0093-5505 |
|---|---|
| Proprietary name | Olanzapine and Fluoxetine |
| Nonproprietary name | Olanzapine and Fluoxetine |
| Substances | OLANZAPINE, FLUOXETINE HYDROCHLORIDE |
| Dosage form | CAPSULE |
| Route | ORAL |
| Labeler | Teva Pharmaceuticals USA, Inc. |
| Product type | HUMAN PRESCRIPTION DRUG |
| Marketing category | ANDA |
| Application number | ANDA077528 |
| Pharmacologic classes | Atypical Antipsychotic [EPC], Serotonin Reuptake Inhibitor [EPC], Serotonin Uptake Inhibitors [MoA] |
| Marketing start | Jun 19, 2012 |
| Listing certified through | Dec 31, 2027 |
At a glance
- 1–9 Package NDCs
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About National Drug Codes (NDC)
The National Drug Code (NDC) is the FDA's product identifier for drugs; the product NDC identifies the labeler and product, and each package adds a package code.
Source: U.S. Food and Drug Administration (FDA), National Drug Code Directory · Source date: